In this eBook, sponsored by Qiagen, we explore the opportunities and challenges of precision oncology and how molecular profiling is fundamental not only to inform on tumor diagnosis and prognosis, but also to drive therapeutic decisions in routine clinical care.
Codevelopment is an intermittent and uncertain process. Adopting an agnostic approach to the challenges associated with platform and method selection provide added degrees of freedom for strategic development and selection of the most appropriate clinical trial assay.
The promise of cell and gene therapies to solve some of our most challenging conditions, from rare diseases to cancers, has led this field to remain on the forefront of innovation. Advances in innovative technologies coupled with deeper scientific knowledge in cellular and molecular biology spurred a new era of growth in these advanced therapies.
2015 was a phenomenal year full of new developments for the structures and mechanisms of CRISPR systems.
Oxford Nanopore’s DNA/RNA sequencing technology delivers ultra-long reads (up to 2 Mb), enabling rapid and comprehensive analysis of variants. With devices scalable from portable to benchtop, nanopore sequencing offers a cost-effective solution to the challenges faced by traditional sequencing platforms.
The challenges of incorporating NGS into clinical trials is being addressed through the adoption of robust technology solutions.
Single-Cell Functional Proteomics Accelerates Immunotherapy Development Opportunities from Pre-Clinical to Clinical Stages
IsoPlexis’ next generation systems provide actionable potency, safety, and patient difference metrics by detecting highly potent single cell functional subsets for the first time.
In this eBook learn how MolecularMD is harnessing the company's unique capabilities to address diagnostic needs within immuno-oncology.
Download this eBook to learn how MolecularMD helped usher in a new era of CML treatment now prescribed by progressive clinicians.
RNA and sequencing technologies have the potential to unlock the mystery of our every dynamic transcriptome.
12Page 1 of 2